Safety of treatments for primary Sjögren’s syndrome

References

• Kroese FGM, Abdulahad WH, Haacke E, et al. B-cell hyperactivity in primary Sjögren’s syndrome. Expert Rev Clin Immunol. 2014;10:483–499.
   PubMed Web of Science ®Google Scholar
• Meijer JM, Meiners PM, Huddleston Slater JJ, et al. Health-related quality of life, employment and disability in patients with Sjogren’s syndrome. Rheumatology (Oxford). 2009;48:1077–1082.
   PubMed Web of Science ®Google Scholar
• Verstappen GM, Kroese FG, Vissink A, et al. Pharmacotherapy for managing extraglandular symptoms of primary Sjögren’s syndrome. Expert Opin Orphan Drugs. 2015;3:125–139.
   Web of Science ®Google Scholar
• Pijpe J, Kalk WWI, Bootsma H, et al. Progression of salivary gland dysfunction in patients with Sjogren’s syndrome. Ann Rheum Dis. 2006;66:107–112.
   PubMed Web of Science ®Google Scholar
• Stevens RJ. Flares of systemic disease in primary Sjogren’s syndrome. Rheumatology. 2005;44:402–403.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Solans R, Rosas J, et al. Primary Sjögren syndrome in Spain. Medicine (Baltimore). 2008;87:210–219.
   PubMed Web of Science ®Google Scholar
• Seror R, Gottenberg JE, Devauchelle-Pensec V, et al. European League against Rheumatism Sjögren’s syndrome disease activity index and European League against Rheumatism Sjögren’s syndrome patient-reported index: a complete picture of primary Sjögren’s syndrome patients. Arthritis Care Res (Hoboken). 2013;65:1358–1364.
   PubMed Web of Science ®Google Scholar
• Seror R, Bootsma H, Saraux A, et al. Defining disease activity states and clinically meaningful improvement in primary Sjögren’s syndrome with EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis. 2016;75:382–389.
   PubMed Web of Science ®Google Scholar
• Ciurtin C, Ostas A, Cojocaru VM, et al. Advances in the treatment of ocular dryness associated with Sjögren׳s syndrome. Semin Arthritis Rheum. 2015;45:321–327.
   PubMed Web of Science ®Google Scholar
• Moshirfar M, Pierson K, Hanamaikai K, et al. Artificial tears potpourri: a literature review. Clin Ophthalmol. 2014;8:1419–1433.
   PubMedGoogle Scholar
• Furrer P, Mayer JM, Gurny R. Ocular tolerance of preservatives and alternatives. Eur J Pharm Biopharm. 2002;53:263–280.
   PubMed Web of Science ®Google Scholar
• Charnock C. Are multidose over-the-counter artificial tears adequately preserved? Cornea. 2006;25:432–437.
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Dogru M, Goto E, et al. Autologous serum application in the treatment of neurotrophic keratopathy. Ophthalmology. 2004;111:1115–1120.
   PubMed Web of Science ®Google Scholar
• Tananuvat N, Daniell M, Sullivan LJ, et al. Controlled study of the use of autologous serum in dry eye patients. Cornea. 2001;20:802–806.
   PubMed Web of Science ®Google Scholar
• Tsubota K, Goto E, Fujita H, et al. Treatment of dry eye by autologous serum application in Sjögren’s syndrome. Br J Ophthalmol. 1999;83:390–395.
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Okamoto S, Mori T, et al. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplant. 2003;31:579–583.
   PubMed Web of Science ®Google Scholar
• Rocha EM, Pelegrino FS, de Paiva CS, et al. GVHD dry eyes treated with autologous serum tears. Bone Marrow Transplant. 2000;25:1101–1103.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, De Paiva CS, Villarreal AL, et al. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-β2 production. Cornea. 2008;27:64–69.
   PubMed Web of Science ®Google Scholar
• Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002;120:330–337.
   PubMed Web of Science ®Google Scholar
• Kunert KS, Tisdale AS, Stern ME, et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol. 2000;118:1489–1496.
   PubMed Web of Science ®Google Scholar
• Demiryay E, Yaylali V, Cetin EN, et al. Effects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome. Eye Contact Lens. 2011;37:312–315.
   PubMed Web of Science ®Google Scholar
• Behrens A, Doyle JJ, Stern L, et al. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea. 2006;25:900–907.
   PubMed Web of Science ®Google Scholar
• Barber LD, Pflugfelder SC, Tauber J, et al. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology. 2005;112:1790–1794.
   PubMed Web of Science ®Google Scholar
• Fakhraie G, Lopes JF, Spaeth GL, et al. Effects of postoperative cyclosporine ophthalmic emulsion 0.05% (Restasis) following glaucoma surgery. Clin Experiment Ophthalmol. 2009;37:842–848.
   PubMed Web of Science ®Google Scholar
• Dursun D, Kim MC, Solomon A, et al. Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline and corticosteroids. Am J Ophthalmol. 2001;132:8–13.
   PubMed Web of Science ®Google Scholar
• Lin T, Gong L. Topical fluorometholone treatment for ocular dryness in patients with Sjögren syndrome: a randomized clinical trial in China. Medicine (Baltimore). 2015;94:e551.
   PubMed Web of Science ®Google Scholar
• Aragona P, Spinella R, Rania L, et al. Safety and efficacy of 0.1% clobetasone butyrate eyedrops in the treatment of dry eye in Sjögren syndrome. Eur J Ophthalmol. 2013;23:368–376.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138:444–457.
   PubMed Web of Science ®Google Scholar
• Lemp MA. Management of dry eye disease. Am J Manag Care. 2008;14:S88–101.
   PubMed Web of Science ®Google Scholar
• Aragona P, Stilo A, Ferreri F, et al. Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjögren’s syndrome patients. Eye (Lond). 2005;19:535–539.
   PubMed Web of Science ®Google Scholar
• Avisar R, Robinson A, Appel I, et al. Diclofenac sodium, 0.1% (Voltaren Ophtha), versus sodium chloride, 5%, in the treatment of filamentary keratitis. Cornea. 2000;19:145–147.
   PubMed Web of Science ®Google Scholar
• Avunduk AM, Avunduk MC, Varnell ED, et al. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol. 2003;136:593–602.
   PubMed Web of Science ®Google Scholar
• Guidera AC, Luchs JI, Udell IJ. Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs. Ophthalmology. 2001;108:936–944.
   PubMed Web of Science ®Google Scholar
• Hsu JKW, Johnston WT, Read RW, et al. Histopathology of corneal melting associated with diclofenac use after refractive surgery. J Cataract Refract Surg. 2003;29:250–256.
   PubMed Web of Science ®Google Scholar
• Sreebny LM, Vissink A. Dry mouth, the malevolent symptom: a clinical guide. Ames: Wiley-Blackwell; 2010.
   Google Scholar
• Regelink G, Vissink A, Reintsema H, et al. Efficacy of a synthetic polymer saliva substitute in reducing oral complaints of patients suffering from irradiation-induced xerostomia. Quintessence Int. 1998;29:383–388.
   PubMed Web of Science ®Google Scholar
• Kielbassa AM, Hinkelbein W, Hellwig E, et al. Radiation-related damage to dentition. Lancet Oncol. 2006;7:326–335.
   PubMed Web of Science ®Google Scholar
• Jansma J, Vissink A, Bouma J, et al. A survey of prevention and treatment regimens for oral sequelae resulting from head and neck radiotherapy used in Dutch radiotherapy institutes. Int J Radiat Oncol Biol Phys. 1992;24:359–367.
   PubMed Web of Science ®Google Scholar
• Marinho VCC, Higgins JPT, Logan S, et al. Topical fluoride (toothpastes, mouthrinses, gels or varnishes) for preventing dental caries in children and adolescents. Cochrane Database Syst Rev. 2003;(4):CD002782. http://www.ncbi.nlm.nih.gov/pubmed/14583954
   Google Scholar
• Fox RI, Konttinen Y, Fisher A. Use of muscarinic agonists in the treatment of Sjögren’s syndrome. Clin Immunol. 2001;101:249–263.
   PubMed Web of Science ®Google Scholar
• Vivino FB, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med. 1999;159:174–181.
   PubMed Web of Science ®Google Scholar
• Papas AS, Sherrer YS, Charney M, et al. Successful treatment of dry mouth and dry eye symptoms in Sjogren’s syndrome patients with oral pilocarpine: a randomized, placebo-controlled, dose-adjustment study. J Clin Rheumatol. 2004;10:169–177.
   PubMed Web of Science ®Google Scholar
• Wu C-H, Hsieh S-C, Lee K-L, et al. Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sjögren’s syndrome in Taiwan–a double-blind, placebo-controlled trial. J Formos Med Assoc. 2006;105:796–803.
   PubMed Web of Science ®Google Scholar
• Tsifetaki N, Kitsos G, Paschides CA, et al. Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren’s syndrome: a randomised 12 week controlled study. Ann Rheum Dis. 2003;62:1204–1207.
   PubMed Web of Science ®Google Scholar
• Kawakita T, Shimmura S, Tsubota K. Effect of oral pilocarpine in treating severe dry eye in patients with Sjögren syndrome. Asia-Pacific J Ophthalmol (Philadelphia, Pa). 2015;4:101–105.
   PubMedGoogle Scholar
• Tomiita M, Takei S, Kuwada N, et al. Efficacy and safety of orally administered pilocarpine hydrochloride for patients with juvenile-onset Sjögren’s syndrome. Mod Rheumatol. 2010;20:486–490.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Matsumoto M, Nakashima M, et al. Effect of cevimeline on salivary components in patients with Sjögren syndrome. Pharmacology. 2005;74:100–105.
   PubMed Web of Science ®Google Scholar
• Leung KCM, McMillan AS, Wong MCM, et al. The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren’s syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study. Clin Rheumatol. 2008;27:429–436.
   PubMed Web of Science ®Google Scholar
• Yamada H, Nakagawa Y, Wakamatsu E, et al. Efficacy prediction of cevimeline in patients with Sjögren’s syndrome. Clin Rheumatol. 2007;26:1320–1327.
   PubMed Web of Science ®Google Scholar
• Ono M, Takamura E, Shinozaki K, et al. Therapeutic effect of cevimeline on dry eye in patients with Sjögren’s syndrome: a randomized, double-blind clinical study. Am J Ophthalmol. 2004;138:6–17.
   PubMed Web of Science ®Google Scholar
• Fife RS, Chase WF, Dore RK, et al. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial. Arch Intern Med. 2002;162:1293–1300.
   PubMedGoogle Scholar
• Petrone D, Condemi JJ, Fife R, et al. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren’s syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum. 2002;46:748–754.
   PubMed Web of Science ®Google Scholar
• Noaiseh G, Baker JF, Vivino FB. Comparison of the discontinuation rates and side-effect profiles of pilocarpine and cevimeline for xerostomia in primary Sjögren’s syndrome. Clin Exp Rheumatol. 2014;32:575–577.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, et al. Topical and systemic medications for the treatment of primary Sjögren’s syndrome. Nat Rev Rheumatol. 2012;8:399–411.
   PubMed Web of Science ®Google Scholar
• Selmi C, Ceribelli A, Naguwa SM, et al. Safety issues and concerns of new immunomodulators in rheumatology. Expert Opin Drug Saf. 2015;14:389–399.
   PubMed Web of Science ®Google Scholar
• Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:529–535.
   PubMed Web of Science ®Google Scholar
• Skopouli FN, Jagiello P, Tsifetaki N, et al.. Methotrexate in primary Sjögren’s syndrome. Clin Exp Rheumatol. 1996;14:555–558.
   PubMed Web of Science ®Google Scholar
• Van Woerkom JM, Kruize AA, Geenen R, et al. Safety and efficacy of leflunomide in primary Sjogren’s syndrome: a phase II pilot study. Ann Rheum Dis. 2007;66:1026–1032.
   PubMed Web of Science ®Google Scholar
• Price EJ, Rigby SP, Clancy U, et al. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren’s syndrome. J Rheumatol. 1998;25:896–899.
   PubMed Web of Science ®Google Scholar
• Willeke P, Schlüter B, Becker H, et al. Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial. Arthritis Res Ther. 2007;9:R115.
   PubMed Web of Science ®Google Scholar
• Drosos AA, Skopouli FN, Galanopoulou VK, et al. Cyclosporin a therapy in patients with primary Sjögren’s syndrome: results at one year. Scand J Rheumatol Suppl. 1986;61:246–249.
   PubMedGoogle Scholar
• Xiong W, Lahita RG. Pragmatic approaches to therapy for systemic lupus erythematosus. Nat Rev Rheumatol. 2014;10:97–107.
   PubMed Web of Science ®Google Scholar
• Migkos MP, Markatseli TE, Iliou C, et al. Effect of hydroxychloroquine on the lipid profile of patients with Sjögren syndrome. J Rheumatol. 2014;41:902–908.
   PubMed Web of Science ®Google Scholar
• Maria NI, Brkic Z, Waris M, et al. MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren’s syndrome. Ann Rheum Dis. 2014;73:1052–1059.
   PubMed Web of Science ®Google Scholar
• Gottenberg J-E, Ravaud P, Puéchal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome. JAMA. 2014;312:249.
   PubMed Web of Science ®Google Scholar
• Kruize AA, Hene RJ, Kallenberg CG, et al. Hydroxychloroquine treatment for primary Sjogren’s syndrome: a two year double blind crossover trial. Ann Rheum Dis. 1993;52:360–364.
   PubMed Web of Science ®Google Scholar
• Marmor MF, Kellner U, Lai TYY, et al. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118:415–422.
   PubMed Web of Science ®Google Scholar
• Costedoat-Chalumeau N, Hulot J-S, Amoura Z, et al. Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. Rheumatology. 2007;46:808–810.
   PubMed Web of Science ®Google Scholar
• Bortoli R, Santiago M. Chloroquine ototoxicity. Clin Rheumatol. 2007;26:1809–1810.
   PubMed Web of Science ®Google Scholar
• Kwon J-B, Kleiner A, Ishida K, et al. Hydroxychloroquine-induced myopathy. J Clin Rheumatol. 2010;16:28–31.
   PubMed Web of Science ®Google Scholar
• Costedoat-Chalumeau N, Amoura Z, Huong DLT, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun Rev. 2005;4:111–115.
   PubMed Web of Science ®Google Scholar
• Motta M, Tincani A, Faden D, et al. Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. J Perinatol. 2005;25:86–89.
   PubMedGoogle Scholar
• Pijpe J, Kalk WW, Bootsma H, et al. Progression of salivary gland dysfunction in patients with Sjogren’s syndrome. Ann Rheum Dis. 2007;66:107–112.
   PubMed Web of Science ®Google Scholar
• Marder W, McCune WJ. Advances in immunosuppressive therapy. Semin Respir Crit Care Med. 2007;28:398–417.
   PubMed Web of Science ®Google Scholar
• Yilmaz N, Emmungil H, Gucenmez S, et al. Incidence of cyclophosphamide-induced urotoxicity and protective effect of mesna in rheumatic diseases. J Rheumatol. 2015;42:1661–1666.
   PubMed Web of Science ®Google Scholar
• Deheinzelin D, Capelozzi VL, Kairalla RA, et al. Interstitial lung disease in primary Sjögren’s syndrome. Clinical-pathological evaluation and response to treatment. Am J Respir Crit Care Med. 1996;154:794–799.
   PubMed Web of Science ®Google Scholar
• Swann PF, Waters TR, Moulton DC, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science. 1996;273:1109–1111.
   PubMed Web of Science ®Google Scholar
• Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40:640–646.
   PubMed Web of Science ®Google Scholar
• Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology (Oxford). 2012;51(Suppl 5):v38–47.
   PubMed Web of Science ®Google Scholar
• Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386:258–265.
   PubMed Web of Science ®Google Scholar
• van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70:414–422.
   PubMed Web of Science ®Google Scholar
• Singh JA, Furst DE, Bharat A, et al. update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;2012(64):625–639.
   Web of Science ®Google Scholar
• Voulgarelis M. Long term remission of Sjogren’s syndrome associated aggressive B cell non-Hodgkin’s lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis. 2006;65:1033–1037.
   PubMed Web of Science ®Google Scholar
• Pollard RPE, Pijpe J, Bootsma H, et al. Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren’s syndrome: a retrospective clinical study. J Rheumatol. 2011;38:2198–2208.
   PubMed Web of Science ®Google Scholar
• Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjogren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62:960–968.
   PubMed Web of Science ®Google Scholar
• Carubbi F, Cipriani P, Marrelli A, et al. Efficacy and safety of rituximab treatment in early primary Sjögren’s syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther. 2013;15:R172.
   PubMed Web of Science ®Google Scholar
• Gottenberg J-E, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjogren’s syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis. 2013;72:1026–1031.
   PubMed Web of Science ®Google Scholar
• Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome. Ann Rheum Dis. 2007;66:351–357.
   PubMed Web of Science ®Google Scholar
• Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis. 2008;67:1541–1544.
   PubMed Web of Science ®Google Scholar
• Moerman RV, Arends S, Meiners PM, et al. EULAR Sjogren’s Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. Ann Rheum Dis. 2014;73:472–474.
   PubMed Web of Science ®Google Scholar
• Meiners PM, Arends S, Brouwer E, et al. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren’s syndrome treated with rituximab. Ann Rheum Dis. 2012;71:1297–1302.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, García-Hernández FJ, de Ramón E, et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol. 2010;28:468–476.
   PubMed Web of Science ®Google Scholar
• Bowman S, Everett C, Bombardieri M, et al. Preliminary results of a double-blind randomised trial of rituximab anti-B-cell therapy in patients with primary Sjogrens syndrome [abstract]. Arthritis Rheumatol (Hoboken, NJ). 2015;67:suppl 10. http://acrabstracts.org/abstract/preliminary-results-of-a-double-blind-randomised-trial-of-rituximab-anti-b-cell-therapy-in-patients-with-primary-sjogrens-syndrome/
   Google Scholar
• Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med. 2014;160:233–242.
   PubMed Web of Science ®Google Scholar
• Pijpe J, van Imhoff GW, Spijkervet FKL, et al. Rituximab treatment in patients with primary Sjögren’s syndrome: an open-label phase II study. Arthritis Rheum. 2005;52:2740–2750.
   PubMed Web of Science ®Google Scholar
• Meijer JM, Pijpe J, Vissink A, et al. Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis. 2009;68:284–285.
   PubMed Web of Science ®Google Scholar
• Devauchelle-Pensec V, Pennec Y, Morvan J, et al. Improvement of Sjögren’s syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 2007;57:310–317.
   PubMed Web of Science ®Google Scholar
• St Clair EW, Levesque MC, Prak ETL, et al. Rituximab therapy for primary Sjögren’s syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum. 2013;65:1097–1106.
   PubMed Web of Science ®Google Scholar
• Pijpe J, Meijer JM, Bootsma H, et al. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjogren’s syndrome. Arthritis Rheum. 2009;60:3251–3256.
   PubMed Web of Science ®Google Scholar
• Gottenberg J-E, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2005;64:913–920.
   PubMed Web of Science ®Google Scholar
• Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;(2):CD008794. http://www.ncbi.nlm.nih.gov/pubmed/21328309
   PubMed Web of Science ®Google Scholar
• Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010;62:2458–2466.
   PubMed Web of Science ®Google Scholar
• Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 2009;10:816–824.
   PubMed Web of Science ®Google Scholar
• Hayashi Y, Kimura A, Kato S, et al. Progressive multifocal leukoencephalopathy and CD4+ T-lymphocytopenia in a patient with Sjögren syndrome. J Neurol Sci. 2008;268:195–198.
   PubMed Web of Science ®Google Scholar
• Hua C, Barnetche T, Combe B, et al. Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2014;66:1016–1026.
   PubMed Web of Science ®Google Scholar
• Steinfeld SD, Tant L, Burmester GR, et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren’s syndrome: an open-label phase I/II study. Arthritis Res Ther. 2006;8:R129.
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. 2014;73:183–190.
   PubMed Web of Science ®Google Scholar
• Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918–3930.
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721–731.
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Wallace DJ, Merrill JT, et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol. 2014;41:300–309.
   PubMed Web of Science ®Google Scholar
• Mariette X, Seror R, Quartuccio L, et al. Efficacy and safety of belimumab in primary Sjogren’s syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis. 2015;74:526–531.
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Navarra S, Petri MA, et al. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus. 2013;22:144–154.
   PubMed Web of Science ®Google Scholar
• De Vita S, Quartuccio L, Seror R, et al. Efficacy and safety of belimumab given for 12 months in primary Sjögren’s syndrome: the BELISS open-label phase II study. Rheumatology (Oxford). 2015;54:2249–2256.
   PubMed Web of Science ®Google Scholar
• Atzeni F, Sarzi-Puttini P, Mutti A, et al. Long-term safety of abatacept in patients with rheumatoid arthritis. Autoimmun Rev. 2013;12:1115–1117.
   PubMed Web of Science ®Google Scholar
• Keystone E, Alkhalaf A, Makkawy M. Subcutaneous abatacept in rheumatoid arthritis: current update. Expert Opin Biol Ther. 2015;15:1221–1230.
   PubMed Web of Science ®Google Scholar
• Meiners PM, Vissink A, Kroese FGM, et al. Abatacept treatment reduces disease activity in early primary Sjogren’s syndrome (open-label proof of concept ASAP study). Ann Rheum Dis. 2014;73:1–4.
   PubMed Web of Science ®Google Scholar
• Adler S, Körner M, Förger F, et al. Evaluation of histological, serological and clinical changes in response to abatacept treatment of primary Sjögren’s syndrome: A pilot study. Arthritis Care Res (Hoboken). 2013;65:1862–1868.
   PubMed Web of Science ®Google Scholar
• Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol. 2009;36:1118–1125.
   PubMed Web of Science ®Google Scholar
• Norheim KB, Harboe E, Goransson LG, et al. Interleukin-1 inhibition and fatigue in primary Sjogren’s syndrome–a double blind, randomised clinical trial. PLoS One. 2012;7:e30123.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Dinarello CA. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford). 2015;54:2134–2144.
   PubMed Web of Science ®Google Scholar
• Sakthiswary R, D’Cruz D. Intravenous immunoglobulin in the therapeutic armamentarium of systemic lupus erythematosus: a systematic review and meta-analysis. Medicine (Baltimore). 2014;93:e86.
   PubMed Web of Science ®Google Scholar
• Orbach H, Katz U, Sherer Y, et al. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol. 2005;29:173–184.
   PubMed Web of Science ®Google Scholar
• Rist S, Sellam J, Hachulla E, et al. Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjögren’s syndrome: a national multicentric retrospective study. Arthritis Care Res (Hoboken). 2011;63:1339–1344.
   PubMed Web of Science ®Google Scholar
• Choung B-S, Yoo W-H. Successful treatment with intravenous immunoglobulin of severe thrombocytopenia complicated in primary Sjögren’s syndrome. Rheumatol Int. 2012;32:1353–1355.
   PubMed Web of Science ®Google Scholar
• David AL, Ataullah I, Yates R, et al. Congenital fetal heart block: a potential therapeutic role for intravenous immunoglobulin. Obstet Gynecol. 2010;116 Suppl:543–547.
   Web of Science ®Google Scholar
• Ii Y, Shindo A, Sasaki R, et al. Reversible stenosis of large cerebral arteries in a patient with combined Sjögren’s syndrome and neuromyelitis optica spectrum disorder. Rheumatol Int. 2008;28:1277–1280.
   PubMed Web of Science ®Google Scholar
• Bienkowska J, Allaire N, Thai A, et al. Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis. PLoS One. 2014;9:e112545.
   PubMed Web of Science ®Google Scholar
• St. Clair W, Baer AN, Noaiseh G, et al. The clinical efficacy and safety of baminercept, a lymphotoxin-beta receptor fusion protein, in primary Sjögren’s syndrome: results from a randomized, double-blind, placebo-controlled phase II trial [abstract]. Arthritis Rheumatol. 2015;67(suppl 10). http://acrabstracts.org/abstract/the-clinical-efficacy-and-safety-of-baminercept-a-lymphotoxin-beta-receptor-fusion-protein-in-primary-sjogrens-syndrome-results-from-a-randomized-double-blind-placebo-controlled-phase-ii-trial/
   Google Scholar
• Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjogren’s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 2004;50:2240–2245.
   PubMed Web of Science ®Google Scholar
• Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjogren’s syndrome: results of the randomized, controlled trial of remicade in primary Sjogren’s syndrome (TRIPSS). Arthritis Rheum. 2004;50:1270–1276.
   PubMed Web of Science ®Google Scholar
• Mavragani CP, Niewold TB, Moutsopoulos NM, et al. Augmented interferon-alpha pathway activation in patients with Sjögren’s syndrome treated with etanercept. Arthritis Rheum. 2007;56:3995–4004.
   PubMed Web of Science ®Google Scholar
• Ioannidis JPA, Evans SJW, Gøtzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141:781–788.
   PubMed Web of Science ®Google Scholar